PARP抑制剂与肿瘤单克隆抗体联用的疗效及机制  

The Mechanism and Effects of Combination Therapy of PARP Inhibitors and Moloclonal Antibodies

作　　者：孙芩玲 潘钰[1] 范丽梅[1] 柳昀熠 邓颖[1] 徐金华[1] SUN Qinling PAN Yu FAN Limei LIU Yunyi DENG Ying XU Jinhua(School of Medicine, Jianghan University, Wuhan, Hubei, 430056, Chin)

机构地区：[1]江汉大学医学院,湖北武汉430056

出　　处：《肿瘤药学》2016年第6期401-406,共6页Anti-Tumor Pharmacy

摘　　要：聚腺苷二磷酸核糖聚合酶(PARP)由于其在DNA损伤修复中的促进作用,已经成为当前肿瘤治疗研究中的热门靶点分子。在某些特定基因型肿瘤中,PARP抑制剂不仅对放化疗有一定的增敏作用,而且还具有显著的单独抗肿瘤效应。近年来,研究发现PARP蛋白在肿瘤细胞对单抗药物产生耐药性的过程中起着一定的推动作用,而多项研究结果已经表明,联合使用PARP抑制剂和单克隆抗体对肿瘤治疗有协同效果。本文将综述联合使用PARP抑制剂和单克隆抗体的最新数据,并讨论它们协同作用的分子机制。Poly（ADP-ribose）polymerase （PARP） proteins have become challenging targets in cancer treatment due to their positive role in DNA damage response. For some cancer patients with specific biomarkers, PARP inhibitors could not only sensitize the radiotherapeutics or chemotherapeuties, but also had anti tumor effect alone. In recent years, it was reported that PARPs are also involved in the tumor drug resistance which was developed during the treatment of the monoclonal antibodies. The combined use of PARP inhibitor and monoclonal antibody has achieved a synergistic therapeutic effect. In this review, we overviewed the therapeutic effects and the molecular mechanisms of the combination of PARP inhibitors with monoelonal antibodies in cancer treatment.

关 键 词：PARP抑制剂 单克隆抗体 肿瘤治疗 

分 类 号：R730.53[医药卫生—肿瘤]